secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001140361-22-044667
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics prices public offering of 20.98M shares at $2.86 for $60M gross proceeds
--------------------------------------------------------------------------------

- Offering of 20,979,020 shares at $2.86/share; gross proceeds ~$60M before expenses.
- Underwriters granted 30-day option to purchase up to 3,146,853 additional shares at same price.
- Closing expected on or about December 9, 2022, subject to customary conditions.
- Net proceeds to accelerate commercialization, production, plasma center buildout, FDA approvals, and R&D.
- Joint book-running managers: Raymond James, Cantor Fitzgerald, and Mizuho Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122044667/0001140361-22-044667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036122044667/ny20006122x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer